Ophthalmic diagnostic device manufacturer ObjectiVision has made its final pitch to the Federal Court at the end of trial in a long-running intellectual property and contract dispute with the University of Sydney, saying in closing submissions that the school had run a “curious” case.
Generic drug maker Alphapharm is fighting a bid by global pharmaceutical giant Sanofi-Aventis to block the listing of one of its injector pens, saying the proposed injunction should be denied because Sanofi is seeking to amend the patent at issue.
A judge has found two patents held by an Eli Lilly & Co. unit for erectile dysfunction drug Cialis are valid and that generic manufacturer Apotex threatened to infringe the patents.
US-based Millennium Pharmaceuticals has secured a temporary injunction that bans generic drug maker Juno Pharmaceuticals from importing or selling its cheap version of breakthrough cancer drug Velcade in Australia.
AstraZeneca is appealing a Fair Work Commission decision that workers are guaranteed 10 days’ sick leave under the National Employment Standards regardless of how long their working day is.
The Full Federal Court has shot down Reckitt Benckiser’s appeal of a ruling that it misled consumers with claims that its Nurofen is a more effective pain killer than rival GlaxoSmithKline’s Panadol.
The Full Federal Court has handed Johnson & Johnson unit Ethicon a victory in the class action over its allegedly defective vaginal mesh devices, partly reversing a judge’s decision that expanded the class post-trial.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy’s Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.
Global pharmaceutical giant Sanofi-Aventis has launched patent infringement proceedings against generic drug maker Alphapharm seeking “urgent interlocutory relief” to prevent a generic injector pen from being listed on the market.
Lawyers on both sides of the class action against American Medical Services over pelvic mesh implants have taken steps to ensure the case proceeds with greater efficiency than the pelvic mesh class action against Johnson & Johnson, which went to an 89-day trial five years after that case was filed.